Intravenous Iron to Improve Symptoms, Quality of Life and Exercise Capacity in HFpEF With Iron Deficiency
A phase 2 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 150 participants.
Also called NCT07643818
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 150 participants
- Sponsor
- Registry
-
NCT07643818
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Jersey
- Registry status
- Enrolling by invitation
Technical summary
Registry record NCT07643818. Randomized; double masking; primary purpose treatment. Start 2026-06-19 (actual); primary completion 2029-07 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Intravenous Iron to Improve Symptoms, Quality of Life and Exercise Capacity in HFpEF With Iron Deficiency
- Acronym
- ISLE HFpEF
- Intervention (Drug)
- Ferric Derisomaltose
- Intervention (Drug)
- Placebo
- Lead sponsor
- Government of Jersey
- Collaborator
- University of Oxford
Record details
- Record id
cardio:ct-nct07643818- Content hash
8ff15b53511609942e27d5bf9190dabb842c4248fc6785269c8a17656282a154